Food and Drug Administration import alerts affecting the following have been newly issued or modified in the past week.
- baby food products from China
- baked goods from China
- bakery products / snack foods from Korea
- broccoli from China
- cabbage from China and Mexico
- chocolate candy bars from Canada
- dried herbs from Hong Kong
- drug products from China
- fruit and vegetable products from China
- green peas from Hungary
- ice cream and related products from China
- kimchi from China
- laser products from China
- limes from Mexico
- macadamia nuts from Kenya
- medical devices from Pakistan
- mouthwash from Colombia
- olive oil from Azerbaijan
- pet chews from Colombia
- plums from China
- potato chips from Mexico
- rice from India and Pakistan
- skin care preparations / cosmetic products from Korea
- shrimp and prawns from India and Indonesia
- strawberries from Mexico
- vitamins and minerals from China and India
Import alerts inform FDA field staff that the agency has enough evidence or other information to allow a product that appears to be in violation of FDA laws and regulations to be detained without physical examination at the time of entry. Import alerts may cover products from designated countries or areas (including from all foreign countries), manufacturers, or shippers.
Firms and/or products on the “red list” of an import alert are subject to DWPE, while firms and/or products on the “green list” are not because they have met the criteria for exclusion. Some import alerts include a “yellow list” of firms, products, and/or countries subject to intensified surveillance because the nature of the violations may warrant further field examinations of individual entries and/or additional analyses. In addition, depending on the specific import alert, shipments of products subject to DWPE may still be imported into the U.S. if the importer has demonstrated that the shipment is in compliance.
If a product is detained without physical examination the importer has the right to provide evidence to the FDA in an attempt to overcome the appearance of the violation. If no such evidence is submitted, or if the evidence provided is insufficient, the product will be subject to refusal of entry into the U.S.
For more information on this and other FDA issues, please contact FDA consultant Domenic Veneziano at (202) 734-3939 or via email.
Copyright © 2025 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.